Azienda Ospedaliera Ospedali Riuniti Marche Nord

Pesaro 13 trials 3 recruiting

13 Registered trials

3 Currently recruiting

Organisation

Azienda Ospedaliera Ospedali Riuniti Marche Nord

Location

Pesaro, Italy

Identifier

ORG-100041781

Address

Piazzale Carlo Cinelli 4, 61121, Italy

Departments

Cardio-oncology and Rare Diseases Unit
Complex Unit of Hematology and Bone Marrow Transplantation Center
DEA
DIVISIONE DI EMATOLOGIA
DIVISIONE DI EMATOLOGIA DI MURAGLIA
Hematology and Stem Cell Transplant Centre
Infectious Diseases
Oncologia
Oncology
U.O.C. Oncologia
UOC Oncologia Marche Nord

Clinical trials at this site (13)

Search interface

A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma posit… Pending

2024-515555-38-01 NON SMALL CELL LUNG CANCER 4
Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h… Recruiting

2023-509717-36-00 AF patients who have undergone successful PCI 5 2024-12-16
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Favorable-intermediate-risk Acute Myeloid Leukemia 5 2020-09-24
Potential protective role of SGLT-2 inhibitors for chemotherapy-induced cardiotoxicity (PROTECT trial) Ended

2024-518611-18-00 Chemotherapy-induced cardiotoxicity in breast cancer 4 2024-12-03
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Metastatic Non–Small Cell Lung Cancer 5 2022-12-01
A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera Ended

2023-509750-58-00 Polycythemia Vera 5 2022-09-21
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Adult Philadelphia Chromosome-Positive Acute Lymphoblas 5 2021-09-08
A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St… Ended

2023-508372-10-00 Non small Cell Lung cancer 4 2021-05-19
The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended

2024-516868-28-00 Ph+ Acute Lymphoblastic Leukemia 4 2021-05-04
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended

2024-513296-41-00 Colorectal cancer spread at distance, RAS BRAF wild typ 4 2020-12-03
Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended

2022-500363-12-00 SARS CoV-2 (COVID-19) 4 2022-08-24
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended

2022-500385-99-00 SARS-CoV II infection (Coronavirus disease) 5 2021-06-03